Considering patient age when treating multiple sclerosis across the adult lifespan

References

• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
   PubMed Web of Science ®Google Scholar
• Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019;15(6):329–342.
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–e1040.
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520–532.
   PubMed Web of Science ®Google Scholar
• Correale J, Gaitan MI, Ysrraelit MC, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140(3):527–546.
   PubMed Web of Science ®Google Scholar
• University of California SFMSET, Cree BA, Gourraud PA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510. https://pubmed.ncbi.nlm.nih.gov/27464262/
   PubMed Web of Science ®Google Scholar
• Schweitzer F, Laurent S, Fink GR, et al. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Curr Opin Neurol. 2019;32(3):305–312.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.
   PubMed Web of Science ®Google Scholar
• Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(Pt 7):1900–1913.
   PubMedGoogle Scholar
• Scalfari A, Neuhaus A, Daumer M, et al. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246–1252.
   PubMed Web of Science ®Google Scholar
• Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013;19(2):188–198.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Horakova D, Bergsland N, et al. A serial 10-year follow-up study of atrophied brain lesion volume and disability progression in patients with relapsing-remitting MS. AJNR Am J Neuroradiol. 2019;40(3):446–452.
   PubMed Web of Science ®Google Scholar
• Ghione E, Bergsland N, Dwyer MG, et al. Aging and brain atrophy in multiple sclerosis. J Neuroimaging. 2019;29(4):527–535.
   PubMed Web of Science ®Google Scholar
• Khademi M, Dring AM, Gilthorpe JD, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 2013;8(5):e63172.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368–1374.
   PubMed Web of Science ®Google Scholar
• Paz Soldan MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology. 2015;84(1):81–88.
   PubMed Web of Science ®Google Scholar
• Conway BL, Zeydan B, Uygunoglu U, et al. Age is a critical determinant in recovery from multiple sclerosis relapses. Mult Scler. 2019;25(13):1754–1763.
   PubMed Web of Science ®Google Scholar
• Novotna M, Paz Soldan MM, Abou Zeid N, et al. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology. 2015;85(8):722–729.
   PubMed Web of Science ®Google Scholar
• Krieger SC, Cook K, De Nino S, et al. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e279.
   PubMed Web of Science ®Google Scholar
• Fuchs TA, Benedict RHB, Bartnik A, et al. Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Hum Brain Mapp. 2019;40(18):5231–5241.
   PubMed Web of Science ®Google Scholar
• Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology. 2016;86(21):2006–2009.
   PubMed Web of Science ®Google Scholar
• Graves JS, Henry RG, Cree BAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018;90(3):e254–e260.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Zivadinov R, Bergsland N, et al. Sex-specific differences in life span brain volumes in multiple sclerosis. J Neuroimaging. 2020;30(3):342–350.
   PubMed Web of Science ®Google Scholar
• Bove R, Healy BC, Musallam A, et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016;22(7):935–943.
   PubMed Web of Science ®Google Scholar
• Baroncini D, Annovazzi PO, De Rossi N, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90(11):1201–1206.
   PubMed Web of Science ®Google Scholar
• Midaglia L, Otero S, Baro F, et al. Menopause and multiple sclerosis: influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. Mult Scler. 2020;1352458520952022. https://pubmed.ncbi.nlm.nih.gov/32856989/
   Web of Science ®Google Scholar
• Ladeira F, Salavisa M, Caetano A, et al. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2018;80(3–4):223–227.
   PubMed Web of Science ®Google Scholar
• Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46.
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019;20(5):299–309.
   PubMed Web of Science ®Google Scholar
• Herbig U, Ferreira M, Condel L, et al. Cellular senescence in aging primates. Science. 2006;311(5765):1257.
   PubMed Web of Science ®Google Scholar
• Habib R, Ocklenburg S, Hoffjan S, et al. Association between shorter leukocyte telomeres and multiple sclerosis. J Neuroimmunol. 2020;341:577187.
   PubMed Web of Science ®Google Scholar
• Guan JZ, Guan WP, Maeda T, et al. Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening. Mol Cell Biochem. 2015;400(1–2):183–187.
   PubMed Web of Science ®Google Scholar
• Krysko KM, Henry RG, Cree BAC, et al. Telomere length is associated with disability progression in multiple sclerosis. Ann Neurol. 2019;86(5):671–682.
   PubMed Web of Science ®Google Scholar
• Njajou OT, Cawthon RM, Damcott CM, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A. 2007;104(29):12135–12139.
   PubMed Web of Science ®Google Scholar
• Heidinger BJ, Blount JD, Boner W, et al. Telomere length in early life predicts lifespan. Proc Natl Acad Sci U S A. 2012;109(5):1743–1748.
   PubMed Web of Science ®Google Scholar
• Cole JH, Raffel J, Friede T, et al. Longitudinal assessment of multiple sclerosis with the brain-age paradigm. Ann Neurol. 2020;88(1):93–105.
   PubMed Web of Science ®Google Scholar
• Hogestol EA, Kaufmann T, Nygaard GO, et al. Cross-sectional and longitudinal MRI brain scans reveal accelerated brain aging in multiple sclerosis. Front Neurol. 2019;10:450.
   PubMed Web of Science ®Google Scholar
• Grebenciucova E, Berger JR. Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep. 2017;17(8):61.
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133–139.
   PubMed Web of Science ®Google Scholar
• Pawelec G, Akbar A, Caruso C, et al. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257–268.
   PubMed Web of Science ®Google Scholar
• Duszczyszyn DA, Williams JL, Mason H, et al. Thymic involution and proliferative T-cell responses in multiple sclerosis. J Neuroimmunol. 2010;221(1–2):73–80.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–590.
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522.
   PubMed Web of Science ®Google Scholar
• Hu WT, Howell JC, Ozturk T, et al. CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunol. 2019;10:480.
   PubMedGoogle Scholar
• Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135(Pt 3):886–899.
   PubMed Web of Science ®Google Scholar
• Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(Pt 7):1914–1924.
   PubMed Web of Science ®Google Scholar
• Nicaise AM, Wagstaff LJ, Willis CM, et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116(18):9030–9039.
   PubMed Web of Science ®Google Scholar
• Wiley CD, Velarde MC, Lecot P, et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016;23(2):303–314.
   PubMed Web of Science ®Google Scholar
• Miller AE, Chitnis T, Cohen BA, et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society. JAMA Neurol. 2020. DOI:10.1001/jamaneurol.2020.4025
   Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405–415.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11(5):420–428.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297–2305.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286–2296.
   PubMed Web of Science ®Google Scholar
• Newsome SD, Kieseier BC, Arnold DL, et al. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. J Neurol. 2016;263(9):1778–1787.
   PubMed Web of Science ®Google Scholar
• Miller AE, O’Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012;18(11):1625–1632.
   PubMed Web of Science ®Google Scholar
• Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182–1193.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273.
   PubMed Web of Science ®Google Scholar
• Signori A, Schiavetti I, Gallo F, et al. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol. 2015;22(6):960–966.
   PubMed Web of Science ®Google Scholar
• Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gonzalez Caldito N, Shirani A, et al. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Ther Adv Neurol Disord. 2020;13:1756286420969016.
   Web of Science ®Google Scholar
• Beiki O, Frumento P, Bottai M, et al. Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden. JAMA Neurol. 2019;76(6):665–671.
   PubMed Web of Science ®Google Scholar
• Amato MP, Fonderico M, Portaccio E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143(10):3013–3024.
   PubMedGoogle Scholar
• Jakimovski D, Dujmic D, Hagemeier J, et al. Late onset multiple sclerosis is associated with more severe ventricle expansion. Mult Scler Relat Disord. 2020;46:102588.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Vaughn CB, Eckert S, et al. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf. 2020;19(9):1121–1142.
   PubMed Web of Science ®Google Scholar
• Fox EJ, Buckle GJ, Singer B, et al. Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist. Neurol Clin Pract. 2019;9(1):53–63.
   PubMedGoogle Scholar
• Wijnands JMA, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050–1056.
   PubMed Web of Science ®Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–191.
   PubMed Web of Science ®Google Scholar
• Zoehner G, Miclea A, Salmen A, et al. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019;12:1756286419878340.
   Web of Science ®Google Scholar
• Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998–1009.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Bermel R, Weber MS, et al. Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal Phase III trials and open-label extensions of ocrelizumab in multiple sclerosis (1173). Neurology. 2020;94(15 Supplement):1173.
   Web of Science ®Google Scholar
• Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Network Open. 2018;1(7):e184169.
   PubMed Web of Science ®Google Scholar
• Mohn N, Pfeuffer S, Ruck T, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e654.
   PubMed Web of Science ®Google Scholar
• Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol. 2005;17(5):378–384.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Haggiag S, Tortorella C, et al. Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler. 2020;1352458520964778. https://pubmed.ncbi.nlm.nih.gov/33104449/
   Web of Science ®Google Scholar
• Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Infections, vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines (Basel). 2020;8(1). DOI:10.3390/vaccines8010050
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2019;93(13):584–594.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Scarpazza C, Imberti L, et al. Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. J Neurovirol. 2017;23(5):742–749.
   PubMed Web of Science ®Google Scholar
• Crooks CV, Cross ML, Wall CR. Age-related differences in integrin expression in peripheral blood lymphocytes. Immun Ageing. 2010;7:5.
   PubMedGoogle Scholar
• Schwab N, Schneider-Hohendorf T, Hoyt T, et al. Anti-JCV serology during natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Mult Scler. 2018;24(5):563–573.
   PubMed Web of Science ®Google Scholar
• Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1. DOI:10.1177/2055217315596994
   PubMedGoogle Scholar
• Briner M, Bagnoud M, Miclea A, et al. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age. Ther Adv Neurol Disord. 2019;12:1756286419843450.
   Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71(16):1261–1267.
   PubMed Web of Science ®Google Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765.
   PubMed Web of Science ®Google Scholar
• Handel AE, Ramagopalan SV. Multiple sclerosis and risk of cancer: a meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81(12):1413–1414.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler. 2015;21(3):294–304.
   PubMed Web of Science ®Google Scholar
• Gaindh D, Kavak KS, Teter B, et al. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. J Neurol Sci. 2016;370:13–17.
   PubMed Web of Science ®Google Scholar
• Zecca C, Disanto G, Sacco R, et al. Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study. J Neurol. 2020. DOI:10.1007/s00415-020-10170-5
   Web of Science ®Google Scholar
• Lo LMP, Taylor BV, Winzenberg T, et al. van der Mei I. Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis. J Neurol. 2020. DOI:10.1007/s00415-020-10194-x
   Web of Science ®Google Scholar
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794–4801.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Vermersch P, Brassat D, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol. 2011;258(7):1304–1311.
   PubMed Web of Science ®Google Scholar
• Ragonese P, Aridon P, Vazzoler G, et al. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol. 2017;17(1):155.
   PubMedGoogle Scholar
• Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opin Biol Ther. 2017;17(9):1163–1172.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426.
   PubMed Web of Science ®Google Scholar
• Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.
   Web of Science ®Google Scholar
• Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86(16):1553–1556.
   PubMed Web of Science ®Google Scholar
• Hajiebrahimi M, Montgomery S, Burkill S, et al. Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients. PLoS One. 2016;11(10):e0165027.
   PubMed Web of Science ®Google Scholar
• Grytten N, Myhr KM, Celius EG, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: a prospective cohort study. Mult Scler. 2020;26(12):1569–1580.
   PubMed Web of Science ®Google Scholar
• Guan Y, Jakimovski D, Ramanathan M, et al. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res. 2019;14(3):373–386.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Chisari CG, Arena S, et al. Cancer risk and multiple sclerosis: evidence from a large Italian Cohort. Front Neurol. 2019;10:337.
   PubMedGoogle Scholar
• Bsteh G, Feige J, Ehling R, et al. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Mult Scler. 2017;23(9):1241–1248.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Kavak K, Vaughn C, et al. Discontinuation of disease modifying therapies in stable ms patients is associated with disability progression regardless of age. (S8.008). Neurology. 2018;90(15 Supplement):S8.008.
   Google Scholar
• McGinley MP, Cola PA, Fox RJ, et al. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Mult Scler. 2020;26(12):1581–1589.
   PubMed Web of Science ®Google Scholar
• Kister I, Spelman T, Alroughani R, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87(10):1133–1137.
   PubMed Web of Science ®Google Scholar
• Hua LH, Fan TH, Conway D, et al. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler. 2019;25(5):699–708.
   PubMed Web of Science ®Google Scholar
• Hua LH, Harris H, Conway D, et al. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60. Mult Scler Relat Disord. 2019;30:252–256.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin Proc. 2014;89(10):1336–1349.
   PubMed Web of Science ®Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13(6):375–382.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72(2):117–124.
   PubMed Web of Science ®Google Scholar
• Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86(14):1287–1295.
   PubMed Web of Science ®Google Scholar
• Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020;20(1):296.
   PubMed Web of Science ®Google Scholar
• Laroni A, Signori A, Maniscalco GT, et al. Assessing association of comorbidities with treatment choice and persistence in MS: a real-life multicenter study. Neurology. 2017;89(22):2222–2229.
   PubMed Web of Science ®Google Scholar
• Sacca F, Lanzillo R, Signori A, et al. Determinants of therapy switch in multiple sclerosis treatment-naive patients: a real-life study. Mult Scler. 2019;25(9):1263–1272.
   PubMed Web of Science ®Google Scholar
• Kowalec K, McKay KA, Patten SB, et al. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology. 2017;89(24):2455–2461.
   PubMed Web of Science ®Google Scholar
• Salter A, Kowalec K, Fitzgerald KC, et al. Comorbidity is associated with disease activity in MS: findings from the CombiRx trial. Neurology. 2020;95(5):e446–e456.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Guan Y, Ramanathan M, et al. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegener Dis Manag. 2019;9(3):149–172.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Sondergaard HB, Laursen JH, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler. 2019;25(9):1298–1305.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Oturai AB, Koch-Henriksen N, et al. Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology. 2018;90(7):e593–e600.
   PubMed Web of Science ®Google Scholar
• Hedstrom AK, Alfredsson L, Lundkvist Ryner M, et al. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler. 2014;20(8):1081–1085.
   PubMed Web of Science ®Google Scholar
• Patel S, SirDeshpande P, Desai R, et al. Thirty-day readmissions in multiple sclerosis: an age and gender-based US national retrospective analysis. Mult Scler Relat Disord. 2019;31:41–50.
   PubMed Web of Science ®Google Scholar
• Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 2016;73(5):520–528.
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–2221.
   PubMed Web of Science ®Google Scholar
• Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179:1084.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Weinstock-Guttman B, Roy S, et al. Cognitive profiles of aging in multiple sclerosis. Front Aging Neurosci. 2019;11:105.
   PubMed Web of Science ®Google Scholar
• Zeydan B, Lowe VJ, Reichard RR, et al. Imaging biomarkers of alzheimer disease in multiple sclerosis. Ann Neurol. 2020;87(4):556–567.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Szigeti K, Jaworski M 3rd, et al. Differential diagnosis of cognitive decline in elderly individuals with multiple sclerosis. Cogn Behav Neurol. 2020;33(4):294–300.
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119(16):3744–3756.
   PubMed Web of Science ®Google Scholar
• Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017;83(11):2367–2376.
   PubMed Web of Science ®Google Scholar
• Ni Gabhann J, Hams E, Smith S, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One. 2014;9(1):e85834.
   PubMed Web of Science ®Google Scholar
• Zrzavy T, Hametner S, Wimmer I, et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900–1913.
   PubMedGoogle Scholar
• Hildesheim FE, Ramasamy DP, Bergsland N, et al. Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Mult Scler Relat Disord. 2020;47:102653.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, Phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185–196.
   PubMed Web of Science ®Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859–873.
   PubMed Web of Science ®Google Scholar